Meeting
2012 ASCO Annual Meeting
Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients.
Authors
Neil Lorne Berinstein
Odette Cancer Centre, Toronto, ON, Canada
Neil Lorne Berinstein , Mohan Karkada , Rita Nigam , Michael Morse , John J. Nemunaitis , Gurkamal S. Chatta , Howard Kaufman , Kunle Odunsi , Genevieve Weir , Lisa MacDonald , Marianne Stanford , Marc Mansour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01095848
Citation
J Clin Oncol 30, 2012 (suppl; abstr 2588)
DOI
10.1200/jco.2012.30.15_suppl.2588
Abstract #
2588
Poster Bd #
7E
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients with induced immune responses and a prolonged OS.
First Author: Yoshihiro Yoshitake
Poster
2014 Genitourinary Cancers Symposium
Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer.
First Author: Ravi Amrit Madan
Poster
2023 ASCO Annual Meeting
H3.3-K27M neoantigen vaccine elicits anti-tumor T cell immunity against diffuse intrinsic pontine glioma: The phase I ENACTING trial.
First Author: Yang Zhang
Poster
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.
First Author: Eric Baudin